IP Library Granted Patent US 10,604,771
Granted Patent B2
US 10,604,771 · App. 14/271,008 · Granted Mar 31, 2020

Delivery methods and compositions for nuclease-mediated genome engineering

Inventors: Paula M. Cannon (Los Angeles, CA); Colin Michael Exline (Los Angeles, CA); Michael C. Holmes (Richmond, CA)
Assignees: Sangamo Therapeutics, Inc.; University of Southern California
C12N15/907A01K2207/12A01K2207/15A01K2267/0381A61K35/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,604,771
App. No.
14/271,008
Granted
Mar 31, 2020
Kind
B2
Abstract

Disclosed herein are methods and compositions for delivery of engineered nucleases and donor molecules into the genome of a cell.

Claims (7)

1. A method of expressing a transgene in an isolated human hematopoietic stem cell (HSC), the method comprising:

a) administering at least one polynucleotide to an isolated human HSC, the polynucleotide encoding a pair of zinc finger nucleases (ZFNs) that generates a double-stranded break in the albumin, CCR5 or AAVS1 gene; and

b) administering a non-viral DNA construct to the human HSC, the DNA construct comprising:

(i) a nucleic acid comprising a transgene encoding a marker protein flanked by nucleic acid sequences homologous to the albumin, CCR5 or AAVS1 gene; and

(ii) a plasmid backbone sequence that is less than 300 base pairs in length and is devoid of bacterial sequences,

wherein the DNA construct does not include an origin of replication, and further wherein the nucleic acid encoding the transgene is integrated into the double-stranded break such that the marker protein is expressed in the isolated human HSC.

2. The method of claim 1 , wherein the DNA construct comprises a promoter that drives expression of the marker protein.

Assignments (3)
CHANGE OF NAME Recorded Feb 6, 2020
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 051837/0624 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2015
From: CANNON, PAULA M.; EXLINE, COLIN MICHAEL
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 037224/0697 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2014
From: HOLMES, MICHAEL C.
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 033215/0996 →
Continuity (2)
Provisional Application 61821872 · May 10, 2013
Related Publication 20140335063A1 · Nov 13, 2014
Cited By (3)
US 12,385,025 US 12,584,149 US 12,735,689